AXSM:NSD-Axsome Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 56.82

Change

+0.60 (+1.07)%

Market Cap

USD 2.54B

Volume

0.33M

Avg Analyst Target

USD 91.05 (+60.24%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

AXSM Stock Forecast & Price:
Based on the Axsome Therapeutics Inc stock forecasts from 10 analysts, the average analyst target price for Axsome Therapeutics Inc is USD 91.05 over the next 12 months. Axsome Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Axsome Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Axsome Therapeutics Inc’s stock price was USD 56.82. Axsome Therapeutics Inc’s stock price has changed by +1.16% over the past week, +41.91% over the past month and +49.80% over the last year.

About Axsome Therapeutics Inc (AXSM:NSD)

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and ...Read More

Company Website : https://www.axsome.com

Address : 22 Cortlandt Street, New York, NY, United States, 10007

Employees : 352

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.75

52 Week High : 71.98

Short Ratio : 5.18

52 Week Low : 20.63

Shorted Shares : 6,230,444

200 Day Moving Average : 40.74

Shorted Shares Previous Month : 5,735,785

50 Day Moving Average : 50.35

Shares Held By Insiders : 18.46%

Short Percentage : 17.59%

Shares Held by Institutions : 61.58%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GILD Gilead Sciences Inc

+0.84 (+0.98%)

 USD106.90B 32.28 22.67
VRTX Vertex Pharmaceuticals Inc

-3.18 (-1.01%)

 USD82.52B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

+0.87 (+0.12%)

 USD81.59B 15.59 11.88
MRNA Moderna Inc

-0.41 (-0.23%)

 USD68.99B 3.18 4.44
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

-1.38 (-0.88%)

 USD37.91B 3.79 1.71
GMAB Genmab AS

+0.34 (+0.77%)

 USD29.03B 36.52 3.47
ALNY Alnylam Pharmaceuticals Inc

+4.23 (+2.03%)

 USD25.76B N/A -27.59
SGEN Seagen Inc

-0.52 (-0.42%)

 USD23.02B 55.02 -41.49
ARGX argenx NV ADR

-2.93 (-0.78%)

 USD20.68B N/A -20.30

ETFs Containing AXSM

Symbol Name Weight Mer Price(Change) Market Cap
DWAQ Invesco DWA NASDAQ Moment.. 0.00 % 0.60 %

N/A

 USD0.05B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 50.40% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.40% 95% A 97% A+
Trailing 12 Months  
Capital Gain 53.90% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.90% 95% A 97% A+
Trailing 5 Years  
Capital Gain 1,003.30% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,003.30% 96% A 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 271.54% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 271.54% 97% A+ 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 571.02% 3% F 2% F
Risk Adjusted Return 47.55% 92% A- 83% B
Market Capitalization 2.54B 93% A 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 15.80 7% F 5% F
Price / Cash Flow Ratio -23.43 91% A- 76% C
EV/EBITDA -15.83 95% A 85% B
Management Effectiveness  
Return on Equity -159.81% 18% F 11% F
Return on Invested Capital -109.95% 20% F 13% F
Return on Assets -41.65% 26% F 10% F
Debt to Equity Ratio 314.07% 5% F 7% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.18 47% F 32% F
Short Percent 17.59% 7% F 8% F
Beta 1.75 20% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector